Genenta Science SpA ADR (GNTA) - Net Assets
Based on the latest financial reports, Genenta Science SpA ADR (GNTA) has net assets worth $12.11 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.55 Million) and total liabilities ($9.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Genenta Science SpA ADR asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.11 Million |
| % of Total Assets | 56.2% |
| Annual Growth Rate | -7.89% |
| 5-Year Change | -17.53% |
| 10-Year Change | N/A |
| Growth Volatility | 74.26 |
Genenta Science SpA ADR - Net Assets Trend (2019–2024)
This chart illustrates how Genenta Science SpA ADR's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Genenta Science SpA ADR for the complete picture of this company's asset base.
Annual Net Assets for Genenta Science SpA ADR (2019–2024)
The table below shows the annual net assets of Genenta Science SpA ADR from 2019 to 2024. For live valuation and market cap data, see GNTA company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $12.50 Million | -38.84% |
| 2023-12-31 | $20.43 Million | -34.38% |
| 2022-12-31 | $31.14 Million | -19.87% |
| 2021-12-31 | $38.86 Million | +156.49% |
| 2020-12-31 | $15.15 Million | -19.63% |
| 2019-12-31 | $18.85 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genenta Science SpA ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4015705900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $68.46 Million | 547.89% |
| Other Comprehensive Income | $88.95K | 0.71% |
| Total Equity | $12.50 Million | 100.00% |
Genenta Science SpA ADR Competitors by Market Cap
The table below lists competitors of Genenta Science SpA ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
US Copper Corp
V:USCU
|
$16.47 Million |
|
Australian Oilseeds Holdings Limited Ordinary Shares
NASDAQ:COOT
|
$16.49 Million |
|
Pan Asia Footwear Public Company Limited
BK:PAF
|
$16.49 Million |
|
Legend Mining Ltd
AU:LEG
|
$16.50 Million |
|
Enzo Biochem Inc
NYSE:ENZ
|
$16.44 Million |
|
BR.SCH.ED.HLD.SP.ADR CL.A
F:BSK0
|
$16.44 Million |
|
Pineapple Financial Inc.
NYSE MKT:PAPL
|
$16.44 Million |
|
Royal Prima PT
JK:PRIM
|
$16.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genenta Science SpA ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 20,432,257 to 12,495,706, a change of -7,936,551 (-38.8%).
- Net loss of 8,912,495 reduced equity.
- Other comprehensive income decreased equity by 142,196.
- Other factors increased equity by 1,118,140.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-8.91 Million | -71.32% |
| Other Comprehensive Income | $-142.20K | -1.14% |
| Other Changes | $1.12 Million | +8.95% |
| Total Change | $- | -38.84% |
Book Value vs Market Value Analysis
This analysis compares Genenta Science SpA ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.67x to 1.03x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.04 | $0.70 | x |
| 2020-12-31 | $0.84 | $0.70 | x |
| 2021-12-31 | $2.13 | $0.70 | x |
| 2022-12-31 | $1.71 | $0.70 | x |
| 2023-12-31 | $1.12 | $0.70 | x |
| 2024-12-31 | $0.68 | $0.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genenta Science SpA ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -71.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-71.32%) is below the historical average (-38.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -24.44% | 0.00% | 0.00x | 1.13x | $-6.49 Million |
| 2020 | -37.00% | 0.00% | 0.00x | 1.16x | $-7.12 Million |
| 2021 | -14.23% | 0.00% | 0.00x | 1.03x | $-9.42 Million |
| 2022 | -27.23% | 0.00% | 0.00x | 1.07x | $-11.59 Million |
| 2023 | -57.00% | 0.00% | 0.00x | 1.09x | $-13.69 Million |
| 2024 | -71.32% | 0.00% | 0.00x | 1.19x | $-10.16 Million |
Industry Comparison
This section compares Genenta Science SpA ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genenta Science SpA ADR (GNTA) | $12.11 Million | -24.44% | 0.78x | $16.45 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more